Hubei JXBio Pharmaceutical Co.,Ltd
FDA inspection history in Xianning, China, 2024 to 2025
- 2
- Form 483s
Every document, by year
- Form 483
2024: one Form 483; 2025: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2024–25Two Form 483s, at Xianning, China.
- 2025The longest 483 on file: 1 observation over 2 pages at Xianning, China.
Cited most
Across all Hubei JXBio Pharmaceutical Co.,Ltd observations on file
- 21 CFR 211.100Written procedures; deviations1
- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.192Production record review1
- 21 CFR 211.25Personnel qualifications1
- 21 CFR 211.67Equipment cleaning and maintenance1
The complete Hubei JXBio Pharmaceutical Co.,Ltd file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Xianning, China
Two Form 483s · 2024 to 2025 · 1 observation
Latest: Form 483, Mar 14, 2025 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2025-03-14 | 483 Form 483 | Xianning, China | 1 | $99 |
| 2024-08-30 | 483 Form 483 | Xianning, China | — | $99 |
Investigators on these documents
FEI number 3016784508 · most recent document Mar 14, 2025
About Hubei JXBio Pharmaceutical Co.,Ltd
How many FDA Form 483s has Hubei JXBio Pharmaceutical Co.,Ltd received?
FDA Intel has 2 Form 483s on file for Hubei JXBio Pharmaceutical Co.,Ltd; the most recent is dated Mar 14, 2025.
When was Hubei JXBio Pharmaceutical Co.,Ltd last inspected by FDA?
The most recent FDA inspection document on file for Hubei JXBio Pharmaceutical Co.,Ltd is a Form 483 dated Mar 14, 2025, for the site in Xianning, China.
What did FDA cite at Hubei JXBio Pharmaceutical Co.,Ltd?
The regulations cited most in the observations on file for Hubei JXBio Pharmaceutical Co.,Ltd are 21 CFR 211.100 (Written procedures; deviations), 1 time; 21 CFR 211.110 (Sampling and testing of in-process materials and drug products), 1 time; 21 CFR 211.192 (Production record review), 1 time.